DE602005026072D1 - Ligand für den formylpeptidrezeptorähnlichen-2 (FPRL2) G Protein gekoppelten Rezeptor - Google Patents

Ligand für den formylpeptidrezeptorähnlichen-2 (FPRL2) G Protein gekoppelten Rezeptor

Info

Publication number
DE602005026072D1
DE602005026072D1 DE602005026072T DE602005026072T DE602005026072D1 DE 602005026072 D1 DE602005026072 D1 DE 602005026072D1 DE 602005026072 T DE602005026072 T DE 602005026072T DE 602005026072 T DE602005026072 T DE 602005026072T DE 602005026072 D1 DE602005026072 D1 DE 602005026072D1
Authority
DE
Germany
Prior art keywords
receptor
protein
fprl2
ligand
formyl peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005026072T
Other languages
English (en)
Inventor
Isabelle Migeotte
Marc Parmentier
David Communi
Maryse Brait
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ogeda SA
Original Assignee
Euroscreen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euroscreen SA filed Critical Euroscreen SA
Publication of DE602005026072D1 publication Critical patent/DE602005026072D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602005026072T 2004-05-14 2005-05-13 Ligand für den formylpeptidrezeptorähnlichen-2 (FPRL2) G Protein gekoppelten Rezeptor Active DE602005026072D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04447122 2004-05-14
EP04447231 2004-10-18

Publications (1)

Publication Number Publication Date
DE602005026072D1 true DE602005026072D1 (de) 2011-03-03

Family

ID=34982585

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602005019495T Active DE602005019495D1 (de) 2004-05-14 2005-05-13 Ligand für den Formylpeptidrezeptorähnlichen- 2 (FPRL2) G Protein gekoppelten Rezeptor und dessen Anwendung
DE602005026072T Active DE602005026072D1 (de) 2004-05-14 2005-05-13 Ligand für den formylpeptidrezeptorähnlichen-2 (FPRL2) G Protein gekoppelten Rezeptor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602005019495T Active DE602005019495D1 (de) 2004-05-14 2005-05-13 Ligand für den Formylpeptidrezeptorähnlichen- 2 (FPRL2) G Protein gekoppelten Rezeptor und dessen Anwendung

Country Status (7)

Country Link
US (3) US7582416B2 (de)
EP (2) EP2020604B1 (de)
JP (2) JP4694887B2 (de)
AT (2) ATE496304T1 (de)
CA (2) CA2810292C (de)
DE (2) DE602005019495D1 (de)
DK (2) DK2020604T3 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4486256B2 (ja) * 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン(PTH)および副甲状腺ホルモン関連ペプチド(PTHrP)の生物活性ペプチドおよびペプチド誘導体
WO2001023521A2 (en) * 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
AU2002339843B2 (en) * 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
WO2004093902A1 (en) * 2003-03-19 2004-11-04 The General Hospital Corporation CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS
WO2005009358A2 (en) 2003-07-17 2005-02-03 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
CA2810292C (en) * 2004-05-14 2015-09-29 Euroscreen S.A. Ligand for g-protein coupled receptor fprl2 and uses thereof
EP2054077A4 (de) * 2006-08-04 2010-10-13 Gen Hospital Corp Polypeptidderivate des parathyroidhormons (pth)
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
WO2008156858A2 (en) * 2007-06-20 2008-12-24 University Of Utah Research Foundation Use of pre-mrna splicing in platelet cells for the diagnosis of disease
US8568737B2 (en) 2007-08-01 2013-10-29 The General Hospital Corporation Screening methods using G-protein coupled receptors and related compositions
CN102239414A (zh) 2008-12-04 2011-11-09 赛诺菲-安万特 牵涉血红素结合蛋白1的方法和用途
ES2431298T3 (es) 2009-05-18 2013-11-25 Actelion Pharmaceuticals Ltd. Derivados de espiro[2.4]heptano puenteados como agonistas del receptor de ALX y/o FPRL2
WO2011073918A2 (en) 2009-12-16 2011-06-23 Actelion Pharmaceuticals Ltd Peptides as modulators of fprl1 and/or fprl2
KR101900078B1 (ko) 2010-05-13 2018-09-18 더 제너럴 하스피탈 코포레이션 부갑상선 호르몬 아날로그 및 그의 용도
EP3314255B1 (de) * 2015-06-25 2019-07-31 H. Hoffnabb-La Roche Ag Zellbasierter assay zur bestimmung von antikörpern oder ligandenbindung und funktion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003345A1 (en) 1988-11-18 1990-05-18 Joel F. Habener Camp-responsive transcriptional enhancer binding protein
EP0605522B1 (de) 1991-09-23 1999-06-23 Medical Research Council Methoden zur Herstellung humanisierter Antikörper
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US7119190B2 (en) * 1997-04-14 2006-10-10 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors
CA2336929C (en) 1998-07-06 2005-10-04 Euroscreen S.A. High-throughput screening diagnostic and/or dosage method of an agonist and/or an antagonist for a calcium-coupled receptor
AU7494200A (en) * 1999-09-15 2001-04-17 Incyte Genomics, Inc. Proteins associated with cell differentiation
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP4184875B2 (ja) * 2002-06-14 2008-11-19 武田薬品工業株式会社 新規スクリーニング方法
CA2810292C (en) * 2004-05-14 2015-09-29 Euroscreen S.A. Ligand for g-protein coupled receptor fprl2 and uses thereof

Also Published As

Publication number Publication date
US7659251B2 (en) 2010-02-09
CA2810292C (en) 2015-09-29
JP4694887B2 (ja) 2011-06-08
EP1607745A2 (de) 2005-12-21
JP2006025787A (ja) 2006-02-02
JP2011078437A (ja) 2011-04-21
JP5314061B2 (ja) 2013-10-16
US7582416B2 (en) 2009-09-01
DK1607745T3 (da) 2010-06-14
CA2504920C (en) 2014-04-01
ATE459004T1 (de) 2010-03-15
EP2020604A1 (de) 2009-02-04
US20060078559A1 (en) 2006-04-13
EP1607745A3 (de) 2006-07-26
EP2020604B1 (de) 2011-01-19
US7842795B2 (en) 2010-11-30
CA2810292A1 (en) 2005-11-14
DE602005019495D1 (de) 2010-04-08
DK2020604T3 (da) 2011-05-16
ATE496304T1 (de) 2011-02-15
US20090053739A1 (en) 2009-02-26
CA2504920A1 (en) 2005-11-14
EP1607745B1 (de) 2010-02-24
US20100009406A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
DE602005026072D1 (de) Ligand für den formylpeptidrezeptorähnlichen-2 (FPRL2) G Protein gekoppelten Rezeptor
HK1211618A1 (en) Nogo receptor binding protein nogo
HK1142272A1 (en) Specific binding proteins and uses thereof
ATE504599T1 (de) Zur aktivierung von rezeptoren fähige fusionspolypeptide
WO2006113602A3 (en) Ascorbate binding peptides
WO2005087811A3 (en) Estrogen receptors and methods of use
WO2007136778A3 (en) Fusion proteins, uses thereof and processes for producing same
WO2005063816A3 (en) Monovalent antibody fragments useful as therapeutics
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
DK1430133T3 (da) En oplöselig Toll-lignende receptor
WO2003001863A3 (en) Novel endothelially expressed dnas and proteins, and their use
EP1578953A4 (de) Verfahren zur bestimmung der primärstruktur der für die rekombinante menschliche endooligopeptidase a (heopa) codierenden boten-rna ¬af217798|...
RU2007142850A (ru) Пептид ded и его применение для идентификации и/или очистки рекомбинантных белков, вектор pded